Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclixatel-pretreated ovarian cancer

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3559-3564

  Polyzos, Aristides ^a,f   Kosmas, Christos ^b   Toufexi, Helen ^a   Malamos, Nicholas ^b   Lagadas, Antonios ^a   Kosmidis, Christos ^a   Ginopoulos, Panagiotis ^c   Ziras, Nicholas ^d   Kandilis, Kostas ^d   Georgoulias, Vassilis ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Cisplatin resistance; Docetaxel; Irinotecan; Ovarian cancer

Indexed keywords

ATROPINE; DEXAMETHASONE; DOCETAXEL; IRINOTECAN; LOPERAMIDE; ONDANSETRON; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; TAXOIDS;

EID: 23344434515     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. McGuire WP, Hoskins WJ, Brady MF et ah Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
2. Piccart MJ, Bertelsen K, James K et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
3. Markman M, Rothman R, Hakes T et al: Second line platinum therapy in patients with cisplatin. J Clin Oncol 9: 389-393, 1991.
4. Eisenhauer EA, Vermorken JB and Van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968, 1997.
5. Swisher EM, Mutch DG, Rader JS et al: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66: 480-486, 1997.
6. Lund B, Hansen OP, Theilade K et al: Phase II study of Gemcitabine (2,′ 2″ - difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994.
7. Bajetta E, Leo AD, Biganzoli L et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14: 2546-2551, 1996.
8. Muggia F, Hamilton A: A phase III data on Caelyx in ovarian cancer. Eur J Cancer 37(suppl 9): S15-S18, 2001.
9. Piccart MJ, Lacare AJ, Reed N et al: Oxaliplatin or paclitaxel in patients with platinum pretreated ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18: 1193-1202, 2000.
10. Fromes Y, Gounon P, Veitia R et al: Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 15: 377-388, 1996.
11. Hanauske AR, Degen D, Hilsenbeck SG et al: Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3: 121-124, 1992.
12. Untch M, Untch A, Sevin BU et al: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with ATP-cell viability assay. Anticancer Drugs 5: 24-30, 1994.
13. Valero V, Jones SE, Von Hoff DD et al: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16: 3362-3368, 1998.
14. Verschraegen CF, Sittisomwong T, Kudelka AP et al: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18(14): 2733-2739, 2000.
15. Francis P, Schneider J, Hann L et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301-2308, 1994.
16. Kavanagh JJ, Kudelka AP, Gonzalez de Leon C et al: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2: 837-842, 1996.
17. Piccart MJ, Gore M, Ten Bokkel Huinink W et al: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87: 676-681, 1995.
18. Katsumata N, Tsunamatsu R, Tanaka K et al: A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese Cooperative Study. Ann Oncol 11: 1531-1536, 2000.
19. Creemers GJ, Bolis G, Gore M et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056-3061, 1996.
20. Kunimoto T, Nitta K, Tanaka T et al: Antitumor activity of 7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivate of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987.
21. Tsuruo T, Matsuzaki T, Matsushia M et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74, 1988.
22. Jansen WJ, Kolfschoten GM, Erkelens CA et al: Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Inst J Cancer 73: 891-896, 1997.
23. O' Meara AT and Sevin BU: In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan). Gynecol Oncol 72: 143-147, 1999.
24. Koshiyama M, Fujii H, Kinezaki M et al: Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin. Anticancer Res 20: 1353-1358, 2000.
25. Takeuchi S, Dobashi K, Fujimoto S et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers. Gan To Kagaku Ryoho 18: 1681-1689, 1991.
26. Sugiyama T, Yakushiji M, Takeuchi S et al : Phase I study of irinotecan (CPT-11) in combination with cisplatin in several and ovarian carcinoma. New York, Proc. 5th Conf. DNA Topoisomerase Therapy, pp. 47, 1994.
27. Sugiyama T, Yakushiji M, Nishida T et al: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128: 211-218, 1998.
28. Sugiyama T, Yakushiji M, Kamura T et al: Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63: 16-22, 2002.
29. Ozols RF: Treatment of recurrent ovarian cancer: increasing option-recurrent results. J Clin Oncol 15: 2177-2180, 1997.
30. Maenpaa JU, Kaar KK, Kivinen ST et al: Docetaxel and CPT-11 for recurrent ovarian cancer. A phase I study. Proc Am Soc Clin Oncol 18: 363a (abstr 1403), 1999.
31. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
32. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
33. Kogmas C, Polyzos A, Tsavaris N et al: Outpatient Taxol®, ifosfamide and cisplatin (TIP) as salvage chemotherapy in pretreated patients with ovarian cancer. Proc Am Soc Clin Oncol 17: 366a (abst 1414), 1998.
34. Maenpaa JU, Ala-Fossi SL, Kivinen ST et al: Docetaxel and irinotecan in the second-line treatment of ovarian cancer: final results of a phase II study. Proc Am Soc Clin Oncol 21: 224a (abstr 894), 2002.
35. Aravantinos G, Bafaloukos D, Fountzilas G et al: Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14(7): 1094-1099, 2003.